» Articles » PMID: 17868902

Dynorphin and the Pathophysiology of Drug Addiction

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2007 Sep 18
PMID 17868902
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Drug addiction is a chronic relapsing disease in which drug administration becomes the primary stimulus that drives behavior regardless of the adverse consequence that may ensue. As drug use becomes more compulsive, motivation for natural rewards that normally drive behavior decreases. The discontinuation of drug use is associated with somatic signs of withdrawal, dysphoria, anxiety, and anhedonia. These consequences of drug use are thought to contribute to the maintenance of drug use and to the reinstatement of compulsive drug use that occurs during the early phase of abstinence. Even, however, after prolonged periods of abstinence, 80-90% of human addicts relapse to addiction, suggesting that repeated drug use produces enduring changes in brain circuits that subserve incentive motivation and stimulus-response (habit) learning. A major goal of addiction research is the identification of the neural mechanisms by which drugs of abuse produce these effects. This article will review data showing that the dynorphin/kappa-opioid receptor (KOPr) system serves an essential function in opposing alterations in behavior and brain neurochemistry that occur as a consequence of repeated drug use and that aberrant activity of this system may not only contribute to the dysregulation of behavior that characterizes addiction but to individual differences in vulnerability to the pharmacological actions of cocaine and alcohol. We will provide evidence that the repeated administration of cocaine and alcohol up-regulates the dynorphin/KOPr system and that pharmacological treatments that target this system may prove effective in the treatment of drug addiction.

Citing Articles

Opioidergic tuning of social attachment: reciprocal relationship between social deprivation and opioid abuse.

Galiza Soares J, Sutley-Koury S, Pomrenze M, Tucciarone J Front Neuroanat. 2025; 18:1521016.

PMID: 39917739 PMC: 11798945. DOI: 10.3389/fnana.2024.1521016.


Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats.

Hrabak M, Ahmed R, Soriano M, Powell A, Thanos P, Steiner H Mol Neurobiol. 2024; 62(4):4520-4532.

PMID: 39466575 DOI: 10.1007/s12035-024-04569-8.


The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female mice.

Wingfield K, Misic T, Jain K, McDermott C, Abney N, Richardson K Psychopharmacology (Berl). 2024; 242(2):427-447.

PMID: 39348003 PMC: 11775077. DOI: 10.1007/s00213-024-06694-7.


Voluntary Exercise Ameliorates Chronic Ethanol Withdrawal-Induced Adaptations of Opioid Receptor Expression in the Nucleus Accumbens, Dopamine Release, and Ethanol Consumption.

Nelson C, Brundage J, Williams B, Baldridge J, Stockard A, Bassett C Biomedicines. 2024; 12(7).

PMID: 39062166 PMC: 11274624. DOI: 10.3390/biomedicines12071593.


The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female mice.

Wingfield K, Misic T, Jain K, McDermott C, Abney N, Richardson K bioRxiv. 2024; .

PMID: 39005445 PMC: 11244951. DOI: 10.1101/2024.07.02.601766.


References
1.
Mucha R, Herz A . Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl). 1985; 86(3):274-80. DOI: 10.1007/BF00432213. View

2.
Heidbreder C, Thompson A, Shippenberg T . Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther. 1996; 278(2):490-502. View

3.
Shippenberg T, Herz A . Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther. 1993; 265(1):53-9. View

4.
McFarland K, Lapish C, Kalivas P . Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci. 2003; 23(8):3531-7. PMC: 6742291. View

5.
Gerfen C, Engber T, Mahan L, Susel Z, Chase T, Monsma Jr F . D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990; 250(4986):1429-32. DOI: 10.1126/science.2147780. View